PYXIS ONCOLOGY, INC.

Analyst Reco. Pyxis Oncology, Inc.

Equities

PYXS

US7473241013

Market Closed - Nasdaq Other stock markets 21:00:00 28/06/2024 BST			5-day change	1st Jan Change
3.31 ^USD	+3.12%		-1.78%	+83.89%

06-10	Pyxis Oncology, Inc. Appoints Michael A. Metzger to Its Board of Directors	CI
05-14	Pyxis Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

H.C. Wainwright Adjusts Price Target on Pyxis Oncology to $7 From $4, Maintains Buy Rating	03-22	MT
BTIG Initiates Pyxis Oncology With Buy Rating, $8 Price Target	02-09	MT
Leerink Partners Initiates Coverage on Pyxis Oncology with Outperform Rating, $12 Price Target	01-23	MT
HC Wainwright Starts Pyxis Oncology With Buy Rating, $4 Price Target	11-30	MT
RBC Initiates Pyxis Oncology at Outperform With Speculative Risk, Sets Price Target at $7, Sees 'Favorable' Risk/Reward	05/09/23	MT
Credit Suisse Starts Pyxis Oncology at Outperform with $19 PT on Potential of Antibody-Drug Conjugate for Cancer	02/11/21	MT
Jefferies Starts Pyxis Oncology at Buy with $25 Price Target	02/11/21	MT
BofA Securities Starts Pyxis Oncology at Neutral With $16 Price Target	02/11/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Our Free Content Help you Secure and Increase the Performance of Your Investments

Securing my Investments

fermer